The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review
    Si Chen
    Yuan Li
    Chuiwen Deng
    Jing Li
    Xiaoting Wen
    Ziyan Wu
    Chaojun Hu
    Shulan Zhang
    Ping Li
    Xuan Zhang
    Fengchun Zhang
    Yongzhe Li
    Rheumatology International, 2016, 36 : 33 - 44
  • [22] Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
    Zhao, Huimin
    Huang, Shanshan
    Wu, Jianyu
    Lu, Yanlan
    Zou, Yue
    Zeng, Haijian
    Li, Chunlan
    Wang, Jin
    Zhang, Xiaochen
    Duan, Siliang
    Liang, Weiming
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [23] The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
    Nie, Run-Cong
    Zhao, Chong-Bang
    Xia, Xiao-Wei
    Luo, Ying-Shan
    Wu, Ting
    Zhou, Zhi-Wei
    Yuan, Shu-Qiang
    Wang, Yun
    Li, Yuan-Fang
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [24] Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
    Celik, Serdar
    Altun, Zekiye Sultan
    Aktas, Safiye
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 18 - 25
  • [25] Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis
    Zhang, Meilin
    Song, Jian
    Yang, Hongguang
    Jin, Feng
    Zheng, Ang
    ACTA ONCOLOGICA, 2022, 61 (09) : 1105 - 1115
  • [26] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Yuwei Liu
    Jiahui Pan
    Fangbo Gao
    Wentao Xu
    Hongyu Li
    Xingshun Qi
    Advances in Therapy, 2023, 40 : 521 - 549
  • [27] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Liu, Yuwei
    Pan, Jiahui
    Gao, Fangbo
    Xu, Wentao
    Li, Hongyu
    Qi, Xingshun
    ADVANCES IN THERAPY, 2023, 40 (02) : 521 - 549
  • [28] Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
    Shen, Kaikai
    Cui, Jinggang
    Wei, Yuqing
    Chen, Xiaojun
    Liu, Guohua
    Gao, Xiaolai
    Li, Wei
    Lu, Huiling
    Zhan, Ping
    Lv, Tangfeng
    Lin, Dang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6636 - 6652
  • [29] Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
    Marek Z. Wojtukiewicz
    Magdalena M. Rek
    Kamil Karpowicz
    Maria Górska
    Barbara Polityńska
    Anna M. Wojtukiewicz
    Marcin Moniuszko
    Piotr Radziwon
    Stephanie C. Tucker
    Kenneth V. Honn
    Cancer and Metastasis Reviews, 2021, 40 : 949 - 982
  • [30] Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-A trial-level meta-analysis in PD-L1 selected subgroups
    Passiglia, Francescoy
    Galvano, Antonio
    Barraco, Nadia
    Castiglia, Marta
    Perez, Alessandro
    La Mantia, Maria
    Russo, Antonio
    Bazan, Viviana
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3106 - +
12345